Edition:
United Kingdom

Cosmo Pharmaceuticals NV (COPN.S)

COPN.S on Swiss Exchange

83.10CHF
12:39pm GMT
Change (% chg)

CHF-0.60 (-0.72%)
Prev Close
CHF83.70
Open
CHF83.40
Day's High
CHF83.50
Day's Low
CHF82.90
Volume
1,914
Avg. Vol
22,379
52-wk High
CHF150.00
52-wk Low
CHF76.10

Chart for

About

COSMO Pharmaceuticals SA is a Luxembourg-based pharmaceutical company engaged in the development and production of drugs against selected gastrointestinal diseases. Its clinical research aims to treat Inflammatory Bowel Diseases (IBD), such as ulcerative colitis and Crohn’s disease, as well as colon infections and skin... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): €1,965.91
Shares Outstanding(Mil.): 15.04
Dividend: --
Yield (%): --

Financials

  COPN.S Industry Sector
P/E (TTM): -- 29.30 32.54
EPS (TTM): 0.24 -- --
ROI: 5.61 14.23 13.82
ROE: 6.12 15.46 15.25

BRIEF-Cosmo Pharmaceuticals Announces Denial Of Methylene Blue MMX Appeal

* COSMO PHARMACEUTICALS ANNOUNCES DENIAL OF METHYLENE BLUE MMX APPEAL AND BEGINNING OF ACTIVITY TO START SECOND PHASE III TRIAL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

12 Mar 2019

BRIEF-Cosmo Pharmaceuticals Files Marketing Authorization Application For Methylene Blue MMX 200 Mg Tablets

* COSMO PHARMACEUTICALS FILES MARKETING AUTHORIZATION APPLICATION FOR METHYLENE BLUE MMX 200 MG TABLETS WITH EUROPEAN MEDICINES AGENCY

12 Feb 2019

BRIEF-Cosmo Pharma Files Marketing Authorization Application For Methylene Blue MMX 200 Mg Tablets With EMA

* COSMO PHARMACEUTICALS FILES MARKETING AUTHORIZATION APPLICATION FOR METHYLENE BLUE MMX 200 MG TABLETS WITH EUROPEAN MEDICINES AGENCY

12 Feb 2019

BRIEF-Cosmo Pharmaceuticals: Regulatory Update For Methylene Blue MMX

* NOW IN PROCESS OF FILING A NEW APPEAL TO OFFICE OF NEW DRUGS (OND), CENTER FOR DRUG EVALUATION AND RESEARCH (CDER) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

21 Dec 2018

BRIEF-Cosmo Pharmaceuticals Launches Offering Of Senior Unsecured Convertible Bonds Due 2023

* LAUNCH OF OFFERING OF SENIOR UNSECURED CONVERTIBLE BONDS DUE 2023

28 Nov 2018

BRIEF-Cosmo Pharmaceuticals: FDA Grants Approval For Aemcolo (Tm) (Rifamycin)

* FDA GRANTS APPROVAL FOR AEMCOLO (TM) (RIFAMYCIN), THE FIRST APPROVED ANTIBIOTIC TO TREAT TRAVELER'S DIARRHEA FOR TEN YEARS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

19 Nov 2018

BRIEF-Cassiopea Enters Into Loan Agreement With Cosmo Pharmaceuticals

* COSMO PHARMACEUTICALS HAS OFFERED AN UNSECURED CREDIT LINE OF EUR 10 MILLION THAT CAN BE INCREASED TO EUR 20 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

11 Oct 2018

Earnings vs. Estimates

No consensus analysis data available.